Lonza Biologics Inc.

The microbial fermentation technology market was valued at USD 31.97 Billion in 2023 and is projected to reach USD 53.25 Billion by 2032, growing at a CAGR of 5.91%. This growth is driven by advancements in biotechnology, demand for sustainable production, and investments in alternative protein companies. Key segments include antibiotics, monoclonal antibodies, and CMOs & CDMOs, with Asia Pacific leading the market and North America poised for fast growth.

Lonza expands services to support smart capsule companies developing oral biologics, offering bespoke development and manufacturing tailored to specific needs. The market for oral biologics is expected to grow at a 35% CAGR from 2023–2028. Lonza also adds bioconjugation capacity at its Visp site, doubling production for bioconjugates by 2028.

MEDIPOST, Inc. appoints five senior executives to lead its U.S. expansion of CARTISTEM, a regenerative therapy for knee osteoarthritis, aiming for IND approval and Phase III clinical trial initiation.

The gene editing market is projected to grow from USD 4.66 billion in 2024 to USD 7.59 billion by 2029, driven by advancements in technologies and expanding applications. The products segment, including kits, reagents, libraries, and software, dominates the market. CRISPR technology leads, while Asia Pacific shows the highest growth rate due to increased R&D and government funding. Challenges include off-target effects and scalability issues.

The Pharmaceutical & Biotechnology Environmental Monitoring Market 2024 report analyzes types (Monitoring Equipment, Media, Software, Microbiology Services), applications (Pharmaceutical Industry, Biotechnology Industry, Academic & Research Institutes), major players (Danaher Corporation, Thermo Fisher Scientific, Eurofins Sinensis, Lonza, Biomerieux, VAI, Cosasco, RMONI, Amphenol Advanced Sensors, Merck KGaA, Vaisal), and regional outlook, forecasting growth from 2024-2032.

K-562 cells cultured in RPMI medium with 10% FBS and 100 µg ml−1 penicillin–streptomycin. hTERT RPE-1 cells in DMEM with similar supplements. RPE-1 p53−/− from Stephen Jackson. CD34+ HSPCs for scRNA-seq in StemSpan SFEM II media. Editing experiments with CD34+ HSPCs in StemSpan SFEM II medium with growth factors. Human upper airway organoids cultured in BME droplets. FIRE reporter cell line generated by lentiviral transduction of K-562 cells. Editing reagents summarized in Supplementary Table 1. Electroporation and DNA repair inhibition detailed. Flow cytometry, gDNA extraction, amplicon sequencing, nanopore sequencing, scRNA-seq, ddPCR, Sanger sequencing, and CAST-seq methods described. Statistical analysis with GraphPad Prism 10.

Lonza expanded its Basel facility to double capacity for biologics drug product quality control, including ADCs and prefilled syringes. The new facility received Swissmedic approval for GMP manufacturing, ensuring safety and regulatory compliance. Key trends include manufacturing demand outpacing supply, driven by complex modalities and patient-friendly treatments. Lonza invests in end-to-end offerings for ADCs and prefilled syringes to meet industry needs, simplifying supply chains and offering agility.

Lonza completes first GMP batch at next-gen mammalian manufacturing facility in Portsmouth, US, meeting market demand for small- to mid-scale biologics.

The Mouse Organoid Culture Medium Market is projected to grow from USD 65.64 million in 2024 to USD 115.56 million by 2030, driven by personalized medicine, chronic disease prevalence, and stem cell research advancements. Key market drivers include personalized medicine demand, 3D cell culture techniques, biotech investments, and disease modeling focus. Challenges include high setup costs, culture complexity, and IP issues. Innovations like serum-free media and IoT-enabled bioreactors are recommended for market opportunities. Major players include Abcam, Amsbio, ATCC, and others.

The Apoptosis Assay Market was valued at USD 5.77 Billion in 2023 and is projected to reach USD 12.86 Billion by 2032, growing at a CAGR of 9.37%. Market growth is fueled by advancements in biotechnology and rising healthcare demands, particularly in oncology and immunology. Key players include Thermo Fisher Scientific, Bio-Rad Laboratories, and others. North America leads the market, while Asia Pacific shows rapid growth potential.